Antonio Gotto

Antonio Gotto, MD, DPhil

Full Member, Research Institute
Houston Methodist
Professor of Medicine, Provost for Medical Affairs & Dean Emeritus, Weill Cornell Medical College


Dr. Antonio M. Gotto is the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York, New York, where he is also Professor of Medicine. In addition, Dr. Gotto is Provost for Medical Affairs of Cornell University. He joined Houston Methodist Research Institute in 2011. Previously, at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor and Chairman of the Department of Medicine, Scientific Director of the DeBakey Heart Center, and the JS Abercrombie Chair for Atherosclerosis and Lipoprotein Research. He also served as Chief of the Internal Medicine Service at The Methodist Hospital in Houston. Dr. Gotto's postgraduate work included doctoral studies at Oxford University in England as a Rhodes Scholar, and residency training at the Massachusetts General Hospital in Boston, Massachusetts.

As a lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. He is a member of the Institute of Medicine and the American Academy of Arts and Sciences and a recipient of many honors, including the Gold Heart Award from the American Heart Association, the 2000 Distinguished Alumnus award from Vanderbilt University and the Vanderbilt University School of Medicine, honorary doctoral degrees from the University of Bologna and Abilene Christian University, honorary professorships from the University of Buenos Aires and Francisco Marroquin University (Guatemala), and the Order of the Lion from the Republic of Finland. Dr. Gotto was the 2004 recipient of the International Okamoto Award from the Japan Vascular Disease Research Foundation. In 2004 Dr. Gotto was also named Honorary Member of the Society for Progress in Internal Medicine (Ludwig Heilmeyer Society) in Germany. In 2010, he received the Maurice R. Greenberg Distinguished Service Award, the highest honor bestowed by New York-Presbyterian/Weill Cornell on members of the medical staff.

Dr. Gotto speaks nationally and internationally on cardiovascular disease and has contributed more than 500 scholarly articles and books to the medical literature. In addition, he is coauthor of a series of books that explain the origins and treatment of cardiovascular disease to the general public.

Description of Research

In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. In addition, Dr. Gotto has played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk of heart disease.

Areas Of Expertise

Lipoproteins and apolipoproteins Atherosclerosis Lipid metabolism Statins
Education & Training

D Phil, University of Oxford
MD, Vanderbilt University

High-density lipoproteins, reverse cholesterol transport and atherogenesis
Pownall, HJ, Rosales, C, Gillard, BK & Gotto, AM 2021, , Nature Reviews Cardiology.

Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo
Yelamanchili, D, Liu, J, Gotto, AM, Hurley, AE, Lagor, WR, Gillard, BK, Davidson, WS, Pownall, HJ & Rosales, C 2020, , Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, vol. 1865, no. 12, 158794.

Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation
Singh, G, Hussain, Y, Xu, Z, Sholle, E, Michalak, K, Dolan, K, Lee, BC, van Rosendael, AR, Fatima, Z, Peña, JM, Wilson, PWF, Gotto, AM, Shaw, LJ, Baskaran, L & Al’Aref, SJ 2020, , PLoS ONE, vol. 15, no. 9 September, e0239934.

The alcohol–high-density lipoprotein athero-protective axis
Rosales, C, Gillard, BK, Gotto, A & Pownall, HJ 2020, , Biomolecules, vol. 10, no. 7, 987, pp. 1-16.

Association of Bempedoic Acid Administration with Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients with Hypercholesterolemia
Banach, M, Duell, PB, Gotto, AM, Laufs, U, Leiter, LA, Mancini, GBJ, Ray, KK, Flaim, JA, Ye, Z & Catapano, AL 2020, , JAMA Cardiology, vol. 5, no. 10, pp. 1124-1135.

Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Bays, HE, Banach, M, Catapano, AL, Duell, PB, Gotto, AM, Laufs, U, Leiter, LA, Mancini, GBJ, Ray, KK, Bloedon, LAT, Sasiela, WJ, Ye, Z & Ballantyne, CM 2020, , Journal of Clinical Lipidology, vol. 14, no. 5, pp. 649-659.e6.

PCSK9 and inflammation: A review of experimental and clinical evidence
Momtazi-Borojeni, AA, Sabouri-Rad, S, Gotto, AM, Pirro, M, Banach, M, Awan, Z, Barreto, GE & Sahebkar, A 2019, , European Heart Journal - Cardiovascular Pharmacotherapy, vol. 5, no. 4, pp. 237-245.

Intensive Lipid Lowering in Elderly Patients
Gotto, AM 2019, , JAMA Cardiology, vol. 4, no. 9, pp. 855-856.

Effects of Conserved Proline- APOA1 Variants on HDL Structure and Function.
Rosales, C, Yelamanchili, D, Gillard, BK, Gotto, A & Pownall, HJ 2019, .

Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials
Simental-Mendía, LE, Pirro, M, Gotto, A, Banach, M, Atkin, SL, Majeed, M & Sahebkar, A 2019, , Critical Reviews in Food Science and Nutrition, vol. 59, no. 7, pp. 1178-1187.

Mammalian Target of Rapamycin: A Metabolic Rheostat for Regulating Adipose Tissue Function and Cardiovascular Health
Wipperman, MF, Montrose, DC, Gotto, AM & Hajjar, DP 2019, , American Journal of Pathology, vol. 189, no. 3, pp. 492-501.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Cholesterol Treatment Trialists Collaboration 2019, , The Lancet, vol. 393, no. 10170, pp. 407-415.

Lipids and Cardiovascular Disease: Putting It All Together
Pownall, HJ & Gotto, A 2019, , Methodist DeBakey cardiovascular journal, vol. 15, no. 1, pp. 5-8.

Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability
Rosales, C, Gillard, BK, Xu, B, Gotto, A & Pownall, HJ 2019, , Methodist DeBakey cardiovascular journal, vol. 15, no. 1, pp. 47-54.

Cholesterol: Can't Live With It, Can't Live Without It
Pownall, HJ & Gotto, A 2019, , Methodist DeBakey cardiovascular journal, vol. 15, no. 1, pp. 9-15.

Extreme hypercholesterolemia in cholestatic sarcoidosis due to lipoprotein X: Exploring the cholesterol gap
Yehya, A, Huang, R, Bernard, DW, Gotto, A & Robbins, RJ 2018, , Journal of Clinical and Translational Endocrinology: Case Reports, vol. 10, pp. 11-13.

In Memoriam: Yuichiro Goto, MD (October 6, 1992 - May 28, 2003)
Matsuzawa, Y, Gotto, AM & Greten, H 2018, , Journal of atherosclerosis and thrombosis, vol. 11, no. 2, pp. 98-100.

Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins
Gillard, BK, Rosales, C, Xu, B, Gotto, AM & Pownall, HJ 2018, , Journal of Clinical Lipidology, vol. 12, no. 4, pp. 849-856.

Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study
ACCORD Study Group 2018, , American Journal of Ophthalmology, vol. 187, pp. 138-147.

Low-density lipoprotein cholesterol and cardiovascular risk reduction: How low is low enough without causing harm?
Gotto, A 2018, , JAMA Cardiology, vol. 3, no. 9, pp. 802-803.